


**Product Name** : ARD-2051  
**Cat. No.** : PC-21161  
**CAS No.** : 2632305-17-8  
**Molecular Formula** : C<sub>43</sub>H<sub>45</sub>ClN<sub>8</sub>O<sub>5</sub>  
**Molecular Weight** : 789.33  
**Target** : PROTAC  
**Solubility** : 10 mM in DMSO



CAS: 2632305-17-8

## Biological Activity

ARD-2051 (ARD-2051) is a potent and orally efficacious **androgen receptor (AR)** proteolysis-targeting chimera (**PROTAC**) degrader with DC50 of 0.6 nM in AR+ VCaP and LNCaP cell lines.

ARD-2051 shows Dmax >90% in inducing AR protein degradation in both the LNCaP and VCaP prostate cancer cell lines, potently and effectively suppresses AR-regulated genes, and inhibits cancer cell growth (VCaP and LNCaP, IC50=10 and 13 nM, respectively).

ARD-2051 (12.5 mg/kg) strongly reduces AR protein and suppresses AR-regulated gene expression in the VCaP xenograft tumor tissue in mice.

ARD-2051 (3.75, 7.5, 15, and 30 mg/kg) effectively inhibited tumor growth in the VCaP xenograft tumor model in SCID mice.

## References

Xin Han, et al. *J Med Chem*. 2023 Jul 13;66(13):8822-8843.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com